Two Down, One To Go: Second Approval Sealed For Ipsen’s Bylvay
FDA Approves Therapy For Alagille Syndrome
Ipsen's oral ileal bile acid transport inhibitor Bylvay is now approved for pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestaisis. However, the biggest opportunity is a third indication – biliary atresia – which could contribute about half of the €800m peak sales predicted by analysts at Jefferies.
